Frontiers in Neurofibromatosis
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (25 March 2023) | Viewed by 36248
Special Issue Editors
Interests: pain; acceptance and commitment therapy; cognitive functioning; medication adherence
Interests: developmental therapeutics; biomarkers; rare tumors
Special Issue Information
Dear Colleagues,
Neurofibromatoses (NF1, NF2, and schwannomatosis) are a group of genetic disorders that can cause cancerous and noncancerous tumors in addition to a variety of other physical, cognitive, and neurobehavioral manifestations. While recent treatment advances have been made for some NF-related symptoms, basic and clinical researchers should strive towards further progress in areas such as cutaneous neurofibromas, optic pathway gliomas, schwannomas, and others. Interventions for helping patients in coping with NF-associated learning disabilities, social impairments, and pain are also warranted. What is also of importance is understanding the most up-to-date techniques for measuring tumor volume and the relationship between tumor volume and functional outcomes.
The goal of this Special Issue in Cancers is to highlight innovations in diagnosis, assessment, and treatment for neurofibromatoses and to point readers towards future research directions. We welcome original research, reviews, and editorials This may be an excellent opportunity for senior researchers to partner up with early-career investigators. We also encourage authors to consider healthcare disparities and/or how their findings apply to diverse patient populations.
Dr. Staci Martin
Dr. Geraldine O'Sullivan Coyne
Dr. Miriam Bornhorst
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurofibromatosis type 1
- neurofibromatosis type 2
- schwannomatosis
- pain
- psychosocial functioning
- mouse models
- optic pathway gliomas
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.